公开(公告)号：US10851175B2

公开(公告)日：2020-12-01

申请号：US15762885

申请日：2016-09-23

Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH ,  GREEN CROSS CORPORATION

Inventor： Dong-Sik Kim ,  Eun Jung Song ,  Mijung Lee ,  Eun-Hee Lee ,  Miyoung Oh ,  Jae Chan Park ,  Kisu Kim ,  Sujeong Kim ,  Hyung-Kwon Lim ,  Kyuhyun Lee ,  Jongwha Won ,  Soongyu Choi ,  Young Seoub Park

IPC: C07K16/18 ,  C07K16/30 ,  C07K16/28

Abstract: The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.

公开(公告)号：US11498965B2

公开(公告)日：2022-11-15

申请号：US16754431

申请日：2018-10-22

Applicant: GREEN CROSS CORPORATION ,  MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： Ki Su Kim ,  Jun Hong Jeong ,  Ae Rin Yoon ,  Eun Jung Song ,  Hye Ji Choi ,  Ok Jae Lim ,  Yun Jung Lee ,  Hyung Kwon Lim ,  Jong Wha Won

IPC: C07K16/28 ,  A61K39/00

Abstract: The present invention relates to an anti-CD3 antibody and a pharmaceutical composition for cancer treatment comprising same. The antibody according to the present invention has high affinity and specificity for CD3 and thus can be effectively used in cancer prevention or treatment.

公开(公告)号：US12098209B2

公开(公告)日：2024-09-24

申请号：US17285367

申请日：2019-10-18

Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： Ki Joon Cho ,  Mijung Lee ,  Eun Jung Song ,  Ki Su Kim ,  Kwan Yub Kang ,  Eui Cheol Cho

IPC: C07K16/28 ,  A61K38/46 ,  A61K39/00 ,  C12N9/16

CPC classification number: C07K16/2869 ,  A61K38/465 ,  C12N9/16 ,  C12Y301/06013 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

Abstract: An asymmetric fusion protein in which a fragment of an antibody binding to an insulin receptor, an iduronate-2-sulfatase (IDS) enzyme, and an Fc region are fused, and a use thereof are disclosed. The fusion protein can cross the blood-brain barrier (BBB) to deliver the IDS enzyme to the brain. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient can be used as a therapeutic agent for a central nervous system disease and particularly, is expected to prevent and treat various diseases caused by ribosome accumulation.

公开(公告)号：US10752697B2

公开(公告)日：2020-08-25

申请号：US15771527

申请日：2016-10-27

Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： Jae Chan Park ,  Kisu Kim ,  Mijung Lee ,  Eun-Hee Lee ,  Dong-Sik Kim ,  Eun Jung Song ,  Sujeong Kim ,  Hyung-Kwon Lim ,  Kyuhyun Lee ,  Jongwha Won ,  Soongyu Choi ,  Young Seoub Park

IPC: C07K16/30 ,  A61K47/68

Abstract: The present invention relates to an antibody specifically binding to glypican 3 (GPC3), a nucleic acid encoding the antibody, a vector and a host cell containing the nucleic acid, a method of preparing the antibody, and a pharmaceutical composition for treating cancer or tumor, containing the antibody as an active ingredient. The antibody specifically binding to glypican 3 according to the present invention may be effectively used to treat cancer or tumor, particularly, hepatocellular carcinoma due to high affinity and specificity to glypican 3.